Korean pharmaceutical companies likely shy of M&A

Companies could benefit from mergers and acquisitions (M&As) in the changing business environment of the 21st century, but Korean drug firms shows a negative attitude towards M&As due to the government’s plan to slash drug prices starting next April.

Both domestic and foreign drug makers are the focus of the government policy. However, Korean drug makers with more original medicines are like...